These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36127888)

  • 1. Soluble FMS-Like Tyrosine Kinase-1: Role in placenta accreta spectrum disorder.
    Lumbanraja S; Yaznil MR; Siahaan AM; Berry Eka Parda B
    F1000Res; 2021; 10():618. PubMed ID: 36127888
    [No Abstract]   [Full Text] [Related]  

  • 2. Distinguishing placenta accreta from placenta previa via maternal plasma levels of sFlt-1 and PLGF and the sFlt-1/PLGF ratio.
    Zhang F; Gu M; Chen P; Wan S; Zhou Q; Lu Y; Li L
    Placenta; 2022 Jun; 124():48-54. PubMed ID: 35635854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The correlation between serum levels and placental tissue expression of PLGF and sFLT-1 and the FIGO grading of the placenta accreta spectrum disorders.
    Alessandrini L; Aryananda R; Ariani G; Agustina B; Akbar MIA; Dachlan EG; Dekker G; Ernawati E
    J Matern Fetal Neonatal Med; 2023 Dec; 36(1):2183744. PubMed ID: 36859823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
    Holme AM; Roland MC; Henriksen T; Michelsen TM
    Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of serum VEGF and sFlt-1 in pernicious placenta previa.
    Wang N; Shi D; Li N; Qi H
    Ann Med; 2021 Dec; 53(1):2041-2049. PubMed ID: 34927512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third-trimester ultrasound for antenatal diagnosis of placenta accreta spectrum in women with placenta previa: results from the ADoPAD study.
    Fratelli N; Prefumo F; Maggi C; Cavalli C; Sciarrone A; Garofalo A; Viora E; Vergani P; Ornaghi S; Betti M; Vaglio Tessitore I; Cavaliere AF; Buongiorno S; Vidiri A; Fabbri E; Ferrazzi E; Maggi V; Cetin I; Frusca T; Ghi T; Kaihura C; Di Pasquo E; Stampalija T; Belcaro C; Quadrifoglio M; Veneziano M; Mecacci F; Simeone S; Locatelli A; Consonni S; Chianchiano N; Labate F; Cromi A; Bertucci E; Facchinetti F; Fichera A; Granata D; D'Antonio F; Foti F; Avagliano L; Bulfamante GP; Calì G;
    Ultrasound Obstet Gynecol; 2022 Sep; 60(3):381-389. PubMed ID: 35247287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between maternal serum sFlt-1 level and placenta accreta spectrum disorders in the third trimester.
    Zhang F; Xia L; Zeng L; You H; Liu Q; Wang Y
    Arch Gynecol Obstet; 2024 Nov; 310(5):2453-2459. PubMed ID: 39287684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective evaluation of impact of post-Cesarean section uterine scarring in perinatal diagnosis of placenta accreta spectrum disorder.
    Hussein AM; Elbarmelgy RA; Elbarmelgy RM; Thabet MM; Jauniaux E
    Ultrasound Obstet Gynecol; 2022 Apr; 59(4):474-482. PubMed ID: 34225385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prenatal ultrasound staging system for placenta accreta spectrum disorders.
    Cali G; Forlani F; Lees C; Timor-Tritsch I; Palacios-Jaraquemada J; Dall'Asta A; Bhide A; Flacco ME; Manzoli L; Labate F; Perino A; Scambia G; D'Antonio F
    Ultrasound Obstet Gynecol; 2019 Jun; 53(6):752-760. PubMed ID: 30834661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of vascular endothelial growth factor and placenta growth factor for placenta accreta spectrum.
    Faraji A; Akbarzadeh-Jahromi M; Bahrami S; Gharamani S; Raeisi Shahraki H; Kasraeian M; Vafaei H; Zare M; Asadi N
    J Obstet Gynaecol; 2022 Jul; 42(5):900-905. PubMed ID: 34558384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between placenta accreta spectrum and third-trimester serum levels of vascular endothelial growth factor, placental growth factor, and soluble Fms-like tyrosine kinase-1: A meta-analysis.
    Alzoubi O; Maaita W; Madain Z; Alzoubi M; Sweis JJG; Arar AR; Sweis NWG
    J Obstet Gynaecol Res; 2022 Sep; 48(9):2363-2376. PubMed ID: 35726123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does soluble fms-like tyrosine kinase-1 regulate placental invasion? Insight from the invasive placenta.
    McMahon K; Karumanchi SA; Stillman IE; Cummings P; Patton D; Easterling T
    Am J Obstet Gynecol; 2014 Jan; 210(1):68.e1-4. PubMed ID: 23994221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of soluble fms-like tyrosine kinase 1 expression in invasive placentation.
    Shainker SA; Dannheim K; Gerson KD; Neo D; Zsengeller ZK; Pernicone E; Karumanchi SA; Hacker MR; Hecht JL
    Arch Gynecol Obstet; 2017 Aug; 296(2):257-262. PubMed ID: 28631072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Angiogenic and Anti-angiogenic Markers in Pregnant Women with Placenta Percreta.
    Uyanıkoğlu H; İncebıyık A; Turp AB; Çakmak G; Sak S; Hilali NG
    Balkan Med J; 2018 Jan; 35(1):55-60. PubMed ID: 28903888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower uterine segment scar assessment at 11-14 weeks' gestation to screen for placenta accreta spectrum in women with prior Cesarean delivery.
    Bhatia A; Palacio M; Wright AM; Yeo GSH
    Ultrasound Obstet Gynecol; 2022 Jan; 59(1):40-48. PubMed ID: 34254386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-Talk between Mucosal-Associated Invariant T, Natural Killer, and Natural Killer T Cell Populations is Implicated in the Pathogenesis of Placenta Accreta Spectrum.
    El-Badawy O; Abbas AM; Radwan E; Makboul R; Khamis AA; Ali M; Elkabsh MM; Bakr MH; Zahran AM
    Inflammation; 2023 Aug; 46(4):1192-1208. PubMed ID: 36997764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentially Preventable Primary Cesarean Sections in Future Placenta Accreta Spectrum.
    Matthews KC; Quinn AS; Chasen ST
    Am J Perinatol; 2022 Jan; 39(2):120-124. PubMed ID: 34784619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Placenta accreta spectrum: a hysterectomy can be prevented in almost 80% of cases using a resective-reconstructive technique.
    Palacios-Jaraquemada JM; Fiorillo A; Hamer J; Martínez M; Bruno C
    J Matern Fetal Neonatal Med; 2022 Jan; 35(2):275-282. PubMed ID: 31984808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Criteria for placenta accreta spectrum in the International Federation of Gynaecology and Obstetrics classification, and topographic invasion area are associated with massive hemorrhage in patients with placenta previa.
    Ishibashi H; Miyamoto M; Iwahashi H; Matsuura H; Kakimoto S; Sakamoto T; Hada T; Takano M
    Acta Obstet Gynecol Scand; 2021 Jun; 100(6):1019-1025. PubMed ID: 33715171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interobserver agreement in MRI assessment of severity of placenta accreta spectrum disorders.
    Finazzo F; D'antonio F; Masselli G; Forlani F; Palacios-Jaraquemada J; Minneci G; Gambarini S; Timor-Tritsch I; Prefumo F; Buca D; Liberati M; Khalil A; Cali G
    Ultrasound Obstet Gynecol; 2020 Apr; 55(4):467-473. PubMed ID: 31237043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.